Exercise Prescription for Established Cardiovascular Disease

Why Exercise Matters More Than Most Medications in Established CVD

Established cardiovascular disease encompasses a history of myocardial infarction, ischemic stroke, peripheral arterial disease (PAD), or symptomatic coronary artery disease confirmed by angiography or stress imaging. In this population, structured physical activity is not a lifestyle recommendation to check off. It is a pharmacologically comparable secondary-prevention strategy.

A 2004 Cochrane systematic review by Taylor et al. Pooled 48 trials (N=8,940) of exercise-based cardiac rehabilitation and found a 20% reduction in total mortality and a 26% reduction in cardiovascular mortality at follow-up periods of 12 months or longer (1). A 2016 update of that same Cochrane review, now encompassing 63 trials and 14,486 participants, confirmed the all-cause mortality reduction at 27% and CVD mortality reduction at 31% (2). Those numbers are comparable to statin therapy in secondary prevention, which reduces CVD events by roughly 25 to 35% in high-risk populations.

Exercise works through multiple mechanisms: improving endothelial function, reducing resting heart rate and blood pressure, attenuating sympathetic nervous system overactivity, increasing insulin sensitivity, and reducing systemic inflammation measured by high-sensitivity CRP.

The Gap Between Evidence and Practice

Despite the evidence, fewer than 25% of eligible post-MI patients in the United States complete a full cardiac rehabilitation program (3). Barriers include geographic access, insurance denials, patient reluctance, and physician under-referral. Telerehabilitation programs have emerged as one response to that access gap, and a 2022 meta-analysis in the Journal of the American Heart Association found home-based cardiac rehab produces equivalent improvements in exercise capacity and quality of life compared to center-based programs (4).

Risk Stratification Before Starting

Not every patient with established CVD starts at the same risk level. Before prescribing moderate-to-vigorous exercise, clinicians should classify patients using the AHA risk stratification model:

• Low risk: Uncomplicated MI or revascularization, LVEF above 50%, no significant arrhythmia, no symptoms at workloads above 5 METs.
• Moderate risk: Mildly impaired LV function (LVEF 40 to 49%), exercise-induced ST changes without symptoms, or mild angina.
• High risk: LVEF below 40%, complex ventricular arrhythmias, hemodynamic instability with exertion, or decompensated heart failure.

High-risk patients should undergo symptom-limited exercise stress testing before beginning any program above light-intensity activity. The AHA/ACC guideline on secondary prevention specifies continuous ECG monitoring for the first 6 to 18 sessions in high-risk patients enrolled in supervised cardiac rehab (5).

Aerobic Exercise: The Foundation of Cardiac Rehabilitation

Aerobic exercise is the most studied modality in CVD secondary prevention. The target is 150 minutes per week of moderate-intensity activity (40 to 60% of heart rate reserve, or 3 to 6 METs) or 75 minutes per week of vigorous-intensity activity (60 to 85% of heart rate reserve, above 6 METs), per the 2019 AHA/ACC Primary Prevention Guideline and the 2024 Physical Activity Guidelines advisory (6).

Moderate-Intensity Continuous Training (MICT)

MICT is the default starting point for most post-MI patients. Sessions typically run 30 to 60 minutes at 50 to 70% of heart rate reserve. Walking, cycling on a stationary ergometer, and swimming are common modalities. MICT reliably improves VO2 peak by 10 to 15% over 12 weeks in stable CAD populations, reduces resting systolic blood pressure by approximately 4 to 8 mmHg, and improves heart rate recovery after exercise, a marker strongly associated with cardiovascular prognosis (7).

Prescribing MICT in post-MI patients with reduced ejection fraction (EF below 40%) requires a conservative starting intensity of 40 to 50% heart rate reserve and sessions of 10 to 15 minutes, building by no more than 5 minutes per session every 1 to 2 weeks.

High-Intensity Interval Training (HIIT)

HIIT involves alternating bouts of high-intensity effort (85 to 95% of peak HR) with active recovery intervals at 50 to 70% of peak HR. A common protocol is 4 x 4 minutes at high intensity with 3-minute active recovery intervals, repeated 3 days per week. This protocol, developed at the Norwegian University of Science and Technology, was tested in SAINTEX-CAD (N=200), a randomized trial comparing HIIT to MICT in stable CAD patients. HIIT produced a mean VO2 peak improvement of 3.6 mL/kg/min versus 2.0 mL/kg/min for MICT at 12 weeks (P<0.001) (8).

Serious cardiac events during HIIT in supervised cardiac rehab programs occur at a rate of approximately 1 per 23,182 patient-hours, which is not meaningfully different from MICT rates (9). HIIT is contraindicated in patients with decompensated heart failure, uncontrolled arrhythmias, severe aortic stenosis, or recent ACS within 3 weeks.

Choosing Between HIIT and MICT

The clinical decision is straightforward. Patients with stable CAD, LVEF above 40%, and a normal stress test response can safely begin HIIT after 4 to 6 weeks of MICT base-building. For patients with LVEF below 40%, prior VT/VF, or significant comorbidities, MICT remains the standard. Adherence matters more than modality. A patient who consistently completes 150 minutes of walking each week will outperform a patient who sporadically attempts HIIT.

Resistance Training in Cardiovascular Disease

Resistance training is no longer considered a secondary option. The AHA Scientific Statement on resistance exercise in adults with and without cardiovascular disease, published in Circulation in 2007 and updated in subsequent guidance, states: "Resistance training is recommended as a component of a comprehensive cardiac rehabilitation program." (10)

Protocols and Safety

For stable CAD with LVEF above 40%, the standard protocol involves:

• 2 sessions per week on non-consecutive days
• 8 to 10 exercises targeting major muscle groups
• 1 to 3 sets of 10 to 15 repetitions per exercise
• Load set at 50 to 80% of one-repetition maximum (1-RM)
• Valsalva maneuver avoided; continuous breathing throughout each repetition

A 2011 meta-analysis by Kelley and Kelley in the Journal of Cardiopulmonary Rehabilitation and Prevention pooled 11 trials of resistance training in cardiac patients and found significant improvements in muscular strength (22% mean increase), VO2 peak (8% mean increase), and quality-of-life scores (11). No significant increase in adverse cardiac events was observed.

Why Muscle Mass Matters for CVD Prognosis

Sarcopenia predicts worse outcomes in cardiovascular disease independent of traditional risk factors. Low appendicular skeletal muscle mass index is associated with a 2.1-fold increased risk of cardiovascular mortality in older adults with coronary artery disease, based on data from the Korean Sarcopenia Study (12). Building and maintaining muscle mass through resistance training addresses that risk directly.

Patients who have undergone coronary artery bypass graft (CABG) surgery should wait 8 to 12 weeks before performing upper-body resistance exercises involving the sternum, and should confirm sternal healing with their surgeon before progressing to chest press or rowing exercises.

Exercise Prescription for Peripheral Arterial Disease

PAD presents a specific clinical challenge: claudication pain limits exercise duration before cardiovascular fatigue, which means patients may not accumulate sufficient cardiovascular stimulus from unsupervised walking alone.

Supervised Treadmill Walking

Supervised treadmill walking is the gold standard for PAD exercise therapy. The established protocol involves walking at a speed that induces moderate claudication pain (3 to 4 on a 5-point claudication scale) within 3 to 5 minutes, then resting until pain resolves, then repeating. Sessions last 30 to 60 minutes and are performed 3 days per week. A meta-analysis by Fakhry et al. In the European Journal of Vascular and Endovascular Surgery (N=1,200+) found supervised treadmill walking improved maximal walking distance by 179 meters and 6-minute walk distance by a mean of 54 meters over 6 to 12 weeks (13).

Alternative Modalities for PAD

Arm ergometry and cycling cause less claudication-limited ischemia and can supplement treadmill walking when leg pain prevents adequate cardiovascular loading. Nordic walking (with poles) distributes effort across upper and lower body and has shown greater improvements in walking distance than standard walking in PAD patients in a randomized trial published in Circulation (14).

Stroke Survivors: Adapted Exercise Protocols

Exercise after ischemic stroke or TIA follows the same general principles as post-MI rehab, with adaptations for neurological deficits. The American Stroke Association recommends that stroke survivors engage in aerobic activity at least 3 days per week, progressing toward 150 minutes per week as functional capacity permits (15).

Functional and Balance Components

Stroke survivors with residual motor deficits benefit from task-specific training, balance exercises, and resistance training targeting affected limbs. These interventions reduce fall risk, a secondary CVD risk factor given the consequences of fall-related inactivity. The LEAPS trial (N=408) demonstrated that a structured home-based exercise program starting at 2 months post-stroke produced equivalent gait improvements to facility-based locomotor training (16).

Aquatic therapy is a particularly useful modality for stroke survivors because water buoyancy reduces fall risk and joint loading, allowing higher movement repetitions than land-based training.

Integrating Pharmacotherapy: The Role of GLP-1 Agonists in Established CVD

Exercise is not the only lifestyle-adjacent intervention with landmark cardiovascular trial data in established CVD. Semaglutide 2.4 mg weekly (Wegovy) achieved a 20% reduction in major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or cardiovascular death) in the SELECT trial (N=17,604), which enrolled adults with a BMI of 27 or above and established CVD but no diabetes, over a mean follow-up of 33 months (17). The hazard ratio was 0.80 (95% CI 0.72 to 0.89, P<0.001).

That MACE benefit appeared independent of the degree of weight loss, suggesting direct cardioprotective mechanisms beyond adiposity reduction. Clinicians treating patients with established CVD and overweight or obesity should consider the SELECT findings when discussing adjunct pharmacotherapy alongside exercise.

Combining Exercise with GLP-1 Therapy: A Clinical Decision Framework

The combination of structured exercise and GLP-1 receptor agonist therapy in established CVD patients warrants a structured approach. Consider the following sequential checklist before initiating concurrent therapy:

1. Confirm CVD category and risk tier (post-MI, symptomatic CAD, PAD, or stroke) using the AHA risk stratification model above.
2. Perform symptom-limited stress test if LVEF is below 40% or if the patient has been sedentary for more than 6 months.
3. Start exercise first for 4 to 6 weeks to establish baseline functional capacity and identify exercise-limiting symptoms.
4. Evaluate BMI and metabolic profile. If BMI is 27 or above with established CVD, SELECT trial data support a discussion about semaglutide 2.4 mg.
5. Monitor for GI side effects during concurrent exercise, as nausea from semaglutide may reduce exercise adherence in the first 8 to 12 weeks. Titrate the dose conservatively (0.25 mg for 4 weeks, then 0.5 mg, then increasing by 0.5 mg every 4 weeks as tolerated).
6. Reassess exercise capacity at 12 weeks using a standardized 6-minute walk test or repeat CPET. Patients on semaglutide who lose significant weight may need exercise intensity upwardly revised.

Practical Exercise Program Structure for New Enrollees

A complete 12-week starter protocol for a low-to-moderate risk patient (post-MI, LVEF above 45%, no complex arrhythmia) looks like this:

Weeks 1 to 2 (Foundation Phase)

• Aerobic: 3 sessions per week, 20 minutes each at 40 to 50% HRR (walking or stationary cycling)
• Resistance: None yet; focus on mobility and breathing technique
• RPE target: 10 to 12 on the Borg 6 to 20 scale

Weeks 3 to 6 (Build Phase)

• Aerobic: 4 sessions per week, 30 to 40 minutes each at 50 to 60% HRR
• Resistance: 2 sessions per week, 8 exercises, 1 to 2 sets, 12 to 15 reps at 40 to 50% 1-RM
• RPE target: 12 to 13

Weeks 7 to 12 (Consolidation Phase)

• Aerobic: 5 sessions per week, 30 to 45 minutes each at 60 to 70% HRR; 1 session may incorporate 2 x 4-minute intervals at 80 to 85% HRR if tolerated
• Resistance: 2 sessions per week, 8 to 10 exercises, 2 to 3 sets, 10 to 12 reps at 60 to 70% 1-RM
• RPE target: 13 to 14

The 150-minute weekly aerobic target is typically achievable by week 5 to 6 in low-risk patients starting from a deconditioned baseline. Progress should stop or reverse temporarily if resting heart rate rises more than 8 to 10 beats per minute above the patient's established baseline on consecutive training days, which suggests incomplete recovery or an emerging illness.

Monitoring and Safety During Exercise

Warning Signs That Require Stopping Exercise

Patients should stop any exercise session and contact their care team or call emergency services for:

• Chest pain, pressure, or tightness at any exercise intensity
• Dizziness or lightheadedness that does not resolve with rest within 3 minutes
• Palpitations that feel rapid or irregular and persist beyond 5 minutes of rest
• Dyspnea that is disproportionate to the exercise load compared to prior sessions
• Syncope or near-syncope

Heart Rate Monitoring

A chest-strap heart rate monitor is more accurate than wrist-based optical sensors during exercise, particularly at higher intensities. Target heart rate zones should be individualized from a maximal or symptom-limited exercise test rather than age-predicted formulas, because beta-blockers, calcium channel blockers, and other common CVD medications significantly attenuate the heart rate response. A patient on metoprolol succinate 100 mg daily may have a peak exercise HR of 110 bpm rather than the age-predicted 160 bpm.

Annual Re-Evaluation

Exercise capacity should be formally re-evaluated at least once per year using a 6-minute walk test, a standardized treadmill protocol, or cardiopulmonary exercise testing (CPET). CPET provides VO2 peak, which is the single strongest prognostic marker in cardiovascular disease. Each 1 mL/kg/min increase in VO2 peak is associated with approximately a 10% reduction in all-cause mortality risk in cardiac populations (18).